XML 46 R40.htm IDEA: XBRL DOCUMENT v3.25.2
License and Collaboration Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable $ 20,925   $ 20,925   $ 20,392
Zai Lab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized   $ 8,000   $ 8,000  
Payment received for additional inventory purchase 16,100   16,100   5,300
Zai Lab | Interim Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 1,400   1,400   600
Amount on net product sales recognized 1,700 0 2,500 0  
Zai Lab | Amended Zai Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized   6,500 600 6,500  
Accounts receivable         1,600
Zai Lab | Manufacturing Stage Transfer Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized 900 0 900 0  
Zai Lab | Research and Development Support | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable 91,000   91,000    
Zai Lab | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 600   1,100    
PAION AG | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable 109,500   109,500    
PAION AG | Cost Reimbursement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 800 0 1,400 0  
PAION AG | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 0 0 $ 0 0  
Everest Medicines Limited          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalties payable period after first commercial sale of product     10 years    
Everest Medicines Limited | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales milestone payments receivable 20,000   $ 20,000    
Everest Medicines Limited | Commercial Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 800 800 $ 1,800 1,700  
Percentage of reimbursed for direct and certain indirect manufacturing costs     110.00%    
Everest Medicines Limited | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 2,000 1,200 $ 2,000 1,800  
George Washington University | GIAPREZA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of royalty payable on net sales     6.00%    
Percentage of royalty on payments received from sublicensees     15.00%    
Royalty expense 1,100 700 $ 2,200 1,400  
Harvard University          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of royalty payable on net sales     5.00%    
Percentage of royalty on payments received from sublicensees     20.00%    
Percentage of minimum royalty rate     4.50%    
Percentage of maximum royalty based on achievement of annual net product sales thresholds     7.50%    
Royalty expense 600 500 $ 700 1,200  
Harvard University | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Clinical development and regulatory milestones amount payable     15,100    
Basilea          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment under intangible asset         $ 4,000
Astrazeneca | Durlobactam          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
One-time Milestone Payment on Net Sales     $ 5,000    
Term of Milestone Payment for Net Sales     3 months    
Royalty expense $ 0 $ 0 $ 0 $ 0  
Astrazeneca | Zoliflodacin          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
One-time Milestone Payment on Commercial Sales     $ 10,000    
Term of Milestone Payment for Commercial Sale     2 years